

Fig. 1




Fig. 2




Fig. 3

Need More Help?

Please let us know what type of Pharmapath user you are, so we can better assist you.

In the form below, we are not seeking any personally identifying information. Your e-mail address and other information will be kept strictly confidential, and will not be shared with any third party.

Describe yourself

☐ Physician office staff member ☐ Physician ☐ Non-physician caregiver ☐ Patient
☐ Member of a patient's family ☐ Other

For Providers and Their Staffs

Describe your practice

☐ Multi-specialty private practice
☐ Single specialty care private practice
☐ Primary care private practice
☐ Non-hospital clinic
☐ Hospital-affiliated clinic

If you are a physician, what is your specialty?

Please Select ▼

If you are on the administrative staff of a practice or clinic:

Please Select ▼

For Patients and Their Families

What type of insurance do you have?
 (more than one may apply)

☐ HMO Plan
☐ PPO Plan
☐ Point of Service or "POS" plan
☐ Blue Cross or Blue Shield plan
☐ Other traditional insurance plan
☐ Medicare
☐ Medicaid
☐ No insurance
☐ Other insurance
☐ Not sure

Fig. 4A

Send us an e-mail with your questions or comments, and we will respond as soon as we can.

E-mail Address

Thanks for your interest in Pharmapath.

Comments

410

Fig. 4B




Fig. 5A




Fig. 5B




Fig. 5C

600

<p>HOME</p> <p>HISTORY OF GLUCOPHAGE®</p> <p>FOR MORE INFORMATION</p> <p>PRESCRIBING INFORMATION</p> <p>RELATED LINKS</p>	<p>Welcome to GLUCOPHAGE.com!</p> <p>Bristol-Myers Squibb, the makers of GLUCOPHAGE® (Metformin Hydrochloride Tablets), is committed to providing helpful information for people with type 2 diabetes, those who care for them, and those who are interested in learning more about diabetes. Our goal is to provide you with information you can start using today.</p> <p>Did you know that there is something better than GLUCOPHAGE®? Visit GLUCOVANCE.com to learn more about this exciting new treatment option!</p>
<p>SIGN UP FOR INFORMATION ON TYPE 2 DIABETES</p> <p>If you would like to be notified about information regarding the management of type 2 diabetes, please enter your e-mail address and then press "Submit."</p> <p>E-MAIL ADDRESS: <input type="text"/></p> <p><input type="button" value="Submit"/></p> <p>See our Privacy Policy to view our commitment and diligence in protecting your privacy.</p>	

Fig. 6A

600

IMPORTANT SAFETY INFORMATION ABOUT GLUCOPHAGE AND GLUCOVANCE

Glucophage and Glucovance are not for everyone. In rare cases, Glucophage or Glucovance may cause lactic acidosis. If it occurs it can be fatal in up to half of the cases. Lactic acidosis occurs mainly in people whose kidneys are not functioning properly. You should not take these drugs if: you have kidney problems, are 80 or older (unless you have your kidneys tested first), are taking medication for heart failure, are seriously dehydrated, have a severe infection, have a history of liver disease or drink alcohol excessively.

The most common side effects are diarrhea, nausea, and upset stomach. Symptoms of hypoglycemia (low blood sugar), such as lightheadedness, dizziness, shakiness, or hunger may occur.

GLUCOVANCE™ is a trademark of LIPHA s.a. GLUCOPHAGE® is a registered trademark of LIPHA s.a. Licensed to Bristol-Myers Squibb Company.

MEDWATCH, 1-800-332-1088, is available to report any serious adverse events for any drug.

Your use of the information on this site is subject to the terms and conditions of our [Legal Policy](#).

Fig. 6B

[DATE] 710

[PAYER NAME] 712

[PAYER ADDRESS] 714

[PAYER CITY, STATE, ZIP] 716

700

Re:

[PATIENT NAME] 718

[DATE OF BIRTH] 720

[PATIENT'S SUBSCRIBER NUMBER] 722

[POLICY ID/GROUP NUMBER] 724

Greetings:

In support of reimbursement for Glucophage® (metformin hydrochloride tablets) for [PATIENT NAME], our clinical examination combined with the patient's history indicate that this patient has type 2, (non-insulin dependent) diabetes (ICD-9-CM code 250.2), and that our first-line approach to managing this condition with diet and exercise is not sufficient to control the blood sugar in this patient.

Our examination and history further indicate that this patient is an ideal candidate for Glucophage.

PICK THE PARAGRAPH FROM THE FOLLOWING THAT APPLIES...

- The patient's blood sugar levels are not adequately controlled with diet and exercise, and requires drug therapy as part of their management plan.

-The patient is obese and metformin therapy is usually not associated with weight gain.

It is my clinical judgment that treatment with metformin is indicated for this patient. I further believe that a failure to reimburse for this drug is to deny this patient access to the standard of care to which he/she is contractually entitled as a member of your health plan.

If you require further documentation regarding this matter, please feel free to contact me at my office.

Sincerely,

[PRESCRIBING PHYSICIAN] 752

[PROVIDER NUMBER]

Fig. 7

Auto Populate

Date	823		829
	822	<input type="text"/>	
Payer Name		<input type="text"/>	823
	824		
Payer Address		<input type="text"/>	825
	826		
Payer City, State, Zip		<input type="text"/>	827
Patient Name	838	<input type="text"/>	831
	832		
Date of Birth		<input type="text"/>	833
Patient's Subscriber Number		<input type="text"/>	835
Patient's Policy and Group ID		<input type="text"/>	837

841 Pick The Paragraphs From The Following Which Apply :

842

☐ Indicia 1 Paragraph
☐ Indicia 2 Paragraph

840

851 If Indicia 1 Was Selected, Pick The Paragraphs From The Following Which Apply :

852

☐ Indicia 3 Paragraph
☐ Indicia 4 Paragraph

850

861 If Indicia 2 Was Selected, Pick The Paragraphs From The Following Which Apply :

862

☐ Indicia 5 Paragraph
☐ Indicia 6 Paragraph
☐ Auto Populate From Local Data Base
☐ Auto Populate From System

860

870

☐ Electronic Signature

Fig. 8



	<div><div>CLARITIN®</div><div>Health plan information for providers and their staffs</div></div>
<div><div>Drug Benefits in the News</div><div>About Company</div><div>Contact Us</div><div>Return to Home</div><div>Terms of Service</div></div>	<div><div>Company provides continuously updated contact information for specific health plans. To access this data, please follow the prompts.</div><div><div><div>1 Find your patient's health plan</div><div>-Please Select Option-</div><div>910</div></div><div><div>2 Find the state level plan for this client</div><div>-Please Select Option-</div><div>920</div></div><div><div>3 Locate the type of plan for this patient</div><div>-Please Select Option-</div><div>940</div></div><div><div>Submit</div><div>960</div></div></div></div>

Fig. 9



Tufts Health Plan

Health plan information for providers and their staffs

1000

<p><u>Drug Benefits</u> in the News</p> <p><u>About</u> Company</p> <p><u>Contact</u> Us</p> <p><u>Return to</u> Home</p> <p><u>Terms of</u> Service</p>	<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>Contact: Joseph F. Gerstein, MD Vice-President/Medical Director for Pharmacy Programs</p> <p>Phone: 800-442-0422 ext. 8569</p> <p>Fax: 800-248-2226</p> <p>Address: 333 Wyman Street</p> <p>City: Waltham State: MA Zip Code: 02254-9112</p> </div> <div style="width: 50%;"> <p>1020</p> <p>Click here for a pre-authorization form</p> <p>1030</p> <p>Click here for a letter of medical necessity</p> <p>Problems or questions? Click here to contact us</p> </div> </div> <p style="text-align: center;">1210</p> <p style="text-align: center;">Click here for a pre-authorization form in PDF.</p> <p style="text-align: right;">1225</p>
--	--

1000

Fig. 10

TUFTS Health Plan

SecureHorizons
TUFTS Health Plan for Seniors

UNIVERSAL PHARMACY MEDICAL EXCEPTION REQUEST FORM

1100 This medical exception request form should be used for all drug products which have restrictions, such as drugs in the Pre-Authorization Program, the Dispensing Limitations Program, non-covered drugs under the Prescription Alternative Program and for New-to-Market drug products for which a coverage determination has yet to be made by Tufts Health Plan.

1110 PLEASE PHOTOCOPY THIS FORM FOR FUTURE REQUESTS
PLEASE TYPE OR PRINT LEGIBLY

I. MEMBER INFORMATION: Tufts HP Use Only: Date Rec'd

NAME: _____

DOB: _____ Date of Request: _____

1120 Tufts Health Plan/Secure Horizons Member ID# _____ (suffix)

1121 II. PRESCRIBER INFORMATION:

Prescriber is: ☐ PCP ☐ Specialist (specify) _____] Other (specify) _____

1122 Prescriber: Name: _____

1123 Address: _____

1124 Telephone: () _____

1130 1125 Fax Number: () _____

1126 Office Contact Person to answer questions: _____

III. PRESCRIBER REQUEST: Request coverage for or increased quantity of:

Name of drug: _____

Strength of drug: _____

Form of drug (e.g. tablet, injectable, nasal spray, topical, etc.): _____

Requested frequency of drug: ☐ once/day ☐ twice/day ☐ three times/day

☐ four times/day ☐ once/week ☐ once/month ☐ other (specify) _____]

Anticipated length of therapy: _____ days _____ weeks _____ months

(Number of days/weeks/months) _____ maintenance _____ other (specify) _____

Fig. 11a

1100

Pertinent patient primary diagnosis for which this drug is indicated (no codes):

Pertinent co-morbid diagnoses (no codes): 1. _____ 2. _____

Pertinent drugs member is currently taking:

1. _____ 2. _____ 3. _____

Page 2

Alternative drugs which failed	PL currently on med? (Y/N)	Reason(s) for failure
1.		1.
2.		2.
3.		3.

In the space provided below, please indicate any other information relevant to this patient that indicates the efficacy of the requested product for the condition in question (i.e. lab data, clinical outcomes, patient symptoms, etc.). Please refer to the guidelines for additional information.

1140

IV. DRUGS WITH ADDITIONAL INFORMATION REQUIRED:

Lamisil (tablets) /Sporanox (capsules) (check all that apply)

***Sporanox is not preferred and will be authorized in special circumstances only.**

Limited to nail surface ☐ YES ☐ NO ☐ Paronychia ☐ Peripheral Vascular Disease

☐ Systemic Fungus (specify): _____ ☐ Immune Deficiency (specify): _____

Injectable Drugs for Multiple Sclerosis (check applicable box below)

***Enclose letter or consult note from Neurologist* - REQUIRED**

☐ Relapsing-Remitting MS

☐ Secondary-Progressive MS

☐ Primary-Progressive MS

☐ Progressive-Relapsing MS

1150 **Anti-Obesity Medications**

_____ Height (in.) in stocking feet Weight (lbs.) in exam gown BMI

1160

PRESCRIBER SIGNATURE: _____ DATE: _____
(REQUIRED)

SEND OR FAX COMPLETED FORM TO:

Tufts Health Plan/Policy Department
PO Box 9112
Waltham, MA 02451-9112
FAX (781) 466-9095

Fig. 11b




Fig. 12

1300

Amarex Insurance Verification Request

Patient's First Name:

Patient's Last Name:

SS#: - -

Date of Birth: January 1 2000

Address:

City: State: ZIP:

Work Telephone: () -

Home Telephone: () -

Primary Insurance (1):

Does this plan include a prescription drug card benefit? ☐ Yes ☐ No

First Name of Insured:

Last Name of Insured:

Relationship to Patient: Relative

Insurance Address:

City: ST: ZIP:

Policy Number:

Group Number:

Insurance Phone: () -

Plan Number:

Type : ☐ Medicare ☐ Medicaid ☐ Indemnity

☐ PPO ☐ HMO ☐ Capitated

☐ Other, please specify:

Secondary Insurance (2):

Does this plan include a prescription drug card benefit? ☐ Yes ☐ No

First Name of Insured:

Last Name of Insured:

Relationship to Patient: Relative

Insurance Address:

Fig. 13A

1300

City: ST: ZIP:

Policy Number:

Group Number:

Insurance Phone: () -

Plan Number:

Name of Employer:

Type : ☐ Medicare ☐ Medicaid ☐ Indemnity
☐ PPO ☐ HMO ☐ Capitated
☐ Other, please specify

Physician's First Name:

Physician's Last Name:

Medicare Provider #:

BC/BS Provider #:

Name of Clinic/Hospital:

Address:

City: State: ZIP:

Telephone: () -

FAX: () -

Name of billing contact:

Telephone (if different): () -

Diagnosis:

Dose & Description of Frequency and Duration/Regimen:

Method of Administration: ☐ SQ ☐ IV infusion ☐ Pump ☐ Other

Where will patient receive Amarex therapy?: ☐ Physician Office ☐ Hospital Inpatient ☐ Hospital Outpatient

Treatment Start/End Date :

Fig. 13B

1400

Amarex Insurance Verification Confirmation

Provider's E-mail address:

PRN:

Patient's Name :

Pre-Authorization Number:

Contact Person at Health Plan:

Health Plan or Other Organization:

Telephone: () -

Comments:

1410

1420

Submit Reset

Fig.14

700240 " 47544 0400

1500

Product Shipment Authorization

PRN#

Refer Questions to (enter reimbursement consultant's name):

Physician Name:

Physician's E-mail Address:

DEA Number:

District Budget:

Patient Name:

Item Number (pick one):
☐ amarixene 400mg, ea; NDC 0002-8701-01; Drug Company's Item Number ZA8701
Number of Vials:
☐ amarixene 800mg, ea; NDC 00002-8702-01; Drug Company's Item Number ZA8702
Number of Vials:

Scheduled administration Date:

Shipping Address:

City: State: ZIP:

Shipping Telephone: () -

1510

Fig. 15




Fig.16

1700

Patient Assistance Program Application

Welcome to the application process for the company's Patient Assistance Program. The drug company has designed the Patient Assistance Program to help patients receiving outpatient therapy who may not otherwise have access to the drug company's products and who meet the program's criteria.

Please enter the information below as requested and click on the "submit" button. Additional directions will follow. If you have any questions, feel free to call 1-888-4Amarex.

We will review the completed application and notify you of the patient's eligibility within two business days of receipt.

Please click [here](#) for full prescribing information.

Patient Information

Patient's First Name:

Patient's Last Name:

Social Security Number: - -

Date of Birth: January 1 2000

Address:

City:

State:

Zip Code:

US Citizen? ☐ Yes ☐ No

Legal Alien? ☐ Yes ☐ No

Dosage and Prescribing Information (Complete for one cycle)

Drug Company's Product Name:

Diagnosis: NSCLC

Dosage:

Fig. 17A

1700

Patient Size: m2

mg/Infusion: mg

Number of Weeks in Cycle:

Insurance Information
(check all that apply)

	Has Benefits	Application Pending	Not Eligible	Has Not Applied
Medicaid	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other State Medical Assistance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Medicare	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Private Insurance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Employer Insurance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Federal (FEHB, VA, CHAMPUS)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other: <input type="text"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Insurance Company Name:

Address Line 1:

Address Line 2:

City: State: ZIP:

Telephone Number: () -

Policyholder Name:

Patient Relationship to Policyholder:

Policy Number:

Group Number:

Fig. 17B

1700

Financial Information	
List Number in Patient's Household (Applicant & Dependents):	<input type="text"/>
Salary/Wages/Pension: \$	<input type="text"/>
Unemployment Compensation: \$	<input type="text"/>
Social Security/Supplemental/Disability: \$	<input type="text"/>
Other (Alimony, Child Support, etc.) \$	<input type="text"/>
Gross Monthly Household Income: \$	<input type="text"/>
Non Covered Medical Expenses	
(Please list out-of-pocket medical expenses)	
Type	<input type="text"/> \$ <input type="text"/>
Type	<input type="text"/> \$ <input type="text"/>
Type	<input type="text"/> \$ <input type="text"/>
Type	<input type="text"/> \$ <input type="text"/>
Type	<input type="text"/> \$ <input type="text"/>
Total Monthly Non Covered Medical Expenses: \$	<input type="text"/>
Provider Information	
Physician Name (include professional designation):	<input type="text"/>
State or License or DEA Number:	<input type="text"/>
Clinic or Hospital:	<input type="text"/>
DEA Address:	<input type="text"/>
City:	<input type="text"/>
State:	<input type="text"/>
ZIP Code:	<input type="text"/>
Application Contact:	<input type="text"/>

Fig. 17C

1700

Telephone: () -

Fax: () -

1710

Fig. 17D

FIG. 17D

FIG. 18

1800

Patient Assistance Program Acceptance E-mail Message

Provider's E-mail Address:

PRN:

Patient's Name:

1810

Fig.18

1900

Patient Assistance Program Denial E-mail Message

Provider's email Address:

Patient's Name:

PRN:

Patient not eligible because:

- ☐ annual income and/or net worth exceeds the maximum allowable under the program.
- ☐ patient outside of US
- ☐ (if other, please specify in body of the following message)

1910

Submit Reset

Fig.19

2000

Product Shipment Authorization

PRN#

Refer Questions to (enter reimbursement consultant's name):

Physician Name:

Physician's E-mail Address:

DEA Number:

District Budget:

Patient Name:

Item Number (pick one):

☐ amarixene 400mg, ea; NDC 0002-8701-01; Drug Company's Item Number ZA8701

Number of Vials:

☐ amarixene 800mg, ea; NDC 00002-8702-01; Drug Company's Item Number ZA8702

Number of Vials:

Scheduled administration Date:

Shipping Address:

City:

State:

ZIP:

Shipping Telephone: (

Submit

Reset

2010

Fig. 20





Fig. 21

2200

amarex

insured patients
uninsured patients
claims assistance



Click here for help
with a specific plan

Reimbursement
Services

plan specific information

Find your patient's health carrier in the list below

Aetna

And find the state level health plan for this patient

Alaska

And find the type of health plan coverage for
this patient

PFS

GO

Fig. 22